N-(Phenylsulfonyl)benzamide Solid Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compounds targeting the Bcl-2 protein family for cancer treatment lack comprehensive studies on polymorphs, amorphous forms, and other structural variations, which affect solubility, stability, and bioavailability, necessitating a thorough examination of crystalline and amorphous forms to enhance drug properties.
Innovation Solution
Development of specific crystalline and amorphous forms of N-(phenyl sulfonyl) benzamide compounds, along with their salts and solvates, characterized by unique XRPD patterns, TGA plots, and DSC curves, to optimize stability, solubility, and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If comprehensive studies on polymorphs and amorphous forms are conducted, then pharmaceutical properties (solubility, stability, bioavailability) are improved, but research time and complexity increase
Solution Approach 1:
The patent performs preliminary identification and characterization of multiple crystalline forms (Forms I-X) and amorphous forms of the Bcl-2 inhibitor compound before clinical development. By systematically preparing and characterizing these forms upfront using XRPD, DSC, and TGA methods, the patent establishes a comprehensive structural database that prevents later surprises during formulation development, thereby improving pharmaceutical properties while managing research time through advance preparation.
2Stability of the object's composition
If multiple crystalline forms are identified and characterized, then drug stability and solubility are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent systematically varies crystallization parameters including solvent types (water, ethanol, isopropanol, acetonitrile, dichloromethane), temperature conditions (room temperature, refrigeration at 4°C, freezing at -20°C), and pH levels to generate and characterize ten distinct crystalline forms. This comprehensive parameter exploration identifies forms with optimized stability and solubility profiles, providing manufacturers with multiple options to select the most suitable form for their specific manufacturing capabilities and product requirements.
Solution Approach 2:
The patent segments the complex polymorph characterization task into ten distinct crystalline forms, each with unique XRPD patterns, DSC curves, and TGA profiles. By systematically isolating and characterizing each form individually with defined preparation methods and characterization data, the patent transforms an overwhelming complexity into manageable, discrete units that can be independently evaluated and selected based on specific manufacturing needs.
3Reliability
If amorphous forms are developed, then bioavailability is improved, but characterization difficulty increases
Solution Approach 1:
The patent uses thermal analysis (DSC and TGA) as intermediary techniques to characterize amorphous forms. These methods provide indirect but reliable information about the amorphous state through thermal transitions, glass transition temperatures, and decomposition behaviors. The XRPD technique serves as another intermediary by detecting the absence of sharp diffraction peaks that would indicate crystalline order, thereby confirming amorphous structure. These intermediary characterization methods make amorphous form identification and validation feasible despite their lack of long-range molecular order.
Data Source
AI summary
The present invention provides crystalline forms or amorphous forms of N-(phenylsulfonyl) benzoamide compound or its salts or solvates used as a Bcl-2 inhibitor, and the preparation method and the application thereof.